Eton Pharmaceuticals Inc (ETON) - News Archive

Eton Pharmaceuticals Takes Bold Step Forward in Fight Against Rare Diseases with Galzin Acquisition In a landmark move signaling its unwavering commitment to rare disease advocacy, Eton Pharmaceuticals, Inc. (NASDAQ: ET...

In the rapidly evolving world of biopharmaceuticals, Eton Pharmaceuticals has recently set a new benchmark with the announcement of the final readout for its groundbreaking clinical trial of PKU GOLIKE. Garnering signif...

In December 2024, Eton Pharmaceuticals, Inc. a company renowned for its commitment to developing therapies for rare diseases, announced the successful acquisition of Increlex (mecasermin injection) from Ipsen S.A. This...

In a significant move that underscores its commitment to patients with ultra-rare conditions, Eton Pharmaceuticals, Inc. has announced the acquisition of Increlex (mecasermin injection) from Ipsen. This strategic decisi...

In an exciting development for Eton Pharmaceuticals, the company recently announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ET-400, a Hydrocortisone Oral Soluti...

Eton Pharmaceuticals Inc. has signaled a major step towards reinforcing its commercial product line with the recent submission to the US Food & Drug Administration (FDA) of the New Drug Application (NDA) for ET-400, a H...

Eton Pharmaceuticals, a leading pharmaceutical company specializing in rare disease treatments, recently announced its acquisition of the U.S. rights to PKU GOLIKE, a groundbreaking medication for Phenylketonuria (PKU)....

Rare diseases affect a small percentage of the population, often making it challenging for pharmaceutical companies to invest in developing treatments. However, Eton Pharmaceuticals, an innovative pharmaceutical company...